Athersys establishes equity purchase facility for sale of up to $100 million of Common Stock to Aspire Capital Fund LLC
Clients Athersys, Inc.
Jones Day represented Athersys, Inc. in connection with the establishment of an equity purchase facility for the sale of up to $100 million of Athersys’ shares of Common Stock to Aspire Capital Fund LLC. Athersys (NASDAQ: ATHX) is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. Athersys is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product.